Compare Abeona Therapeutics Inc (ABEO) vs Wipro Limited (WIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Wipro Limited — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Wipro Limited trades at $1.84 (market cap $18.14B). The key difference: Wipro Limited is far larger — about 48.6× Abeona Therapeutics Inc's market cap, and Wipro Limited pays a 10.37% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WIT | |
|---|---|---|
Market Cap | $373.32M | $18.14B |
Sector | Health | Technology |
52-Week High | $7.23 | $3.09 |
52-Week Low | $4.17 | $1.82 |
Enterprise Value | $228.22M | $14.53B |
Dividend Yield | — | 10.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
WIT trades at $1.85, down 2.12% today, with a bearish technical signal from moving averages. The company reported revenue of $890.88B in 2025 with a net income margin of 14.25% and a P/E ratio of 13.82. Recent earnings have missed estimates for three consecutive quarters, and analyst sentiment is mixed with a Hold consensus. News highlights include AI partnerships and a weak Q2 2026 revenue outlook.
The outlook is cautious due to near-term revenue pressure and earnings misses, though valuation appears reasonable. Risks include client spending caution and competitive pressures. Upside may depend on AI-driven growth initiatives and large deal execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
